The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients
降钙素原与生存研究 (PASS) 是一项随机、多中心、研究者发起的试验，旨在探讨每日测量生物标志物降钙素原以及对异常降钙素原水平采取积极的诊断和治疗措施是否能够提高重症监护病房患者的生存率。计算样本量（目标人群）：1000 名患者
期刊:BMC Infectious Diseases
影响因子:3
doi:10.1186/1471-2334-8-91
Jensen, Jens-Ulrik; Lundgren, Bettina; Hein, Lars; Mohr, Thomas; Petersen, Pernille L; Andersen, Lasse H; Lauritsen, Anne O; Hougaard, Sine; Mantoni, Teit; Bømler, Bonnie; Thornberg, Klaus J; Thormar, Katrin; Løken, Jesper; Steensen, Morten; Carl, Peder; Petersen, J Asger; Tousi, Hamid; Søe-Jensen, Peter; Bestle, Morten; Hestad, Søren; Andersen, Mads H; Fjeldborg, Paul; Larsen, Kim M; Rossau, Charlotte; Thomsen, Carsten B; Ostergaard, Christian; Kjaer, Jesper; Grarup, Jesper; Lundgren, Jens D
